Literature DB >> 25127163

Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.

Emanuele Amata1, Nicholas D Bland2, Charles T Hoyt1, Luca Settimo1, Robert K Campbell2, Michael P Pollastri1.   

Abstract

A medicinal chemistry exploration of the human phosphodiesterase 4 (hPDE4) inhibitor cilomilast (1) was undertaken in order to identify inhibitors of phosphodiesterase B1 of Trypanosoma brucei (TbrPDEB1). T. brucei is the parasite which causes African sleeping sickness, a neglected tropical disease that affects thousands each year, and TbrPDEB1 has been shown to be an essential target of therapeutic relevance. Noting that 1 is a weak inhibitor of TbrPDEB1, we report the design and synthesis of analogs of this compound, culminating in 12b, a sub-micromolar inhibitor of TbrPDEB1 that shows modest inhibition of T. brucei proliferation.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiprotozoal agents; Cilomilast; Phosphodiesterase inhibitors; TbrPDEB1 Trypanosoma brucei

Mesh:

Substances:

Year:  2014        PMID: 25127163      PMCID: PMC4155488          DOI: 10.1016/j.bmcl.2014.07.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  18 in total

1.  Strength of the Calpha H..O hydrogen bond of amino acid residues.

Authors:  S Scheiner; T Kar; Y Gu
Journal:  J Biol Chem       Date:  2001-01-04       Impact factor: 5.157

2.  Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

Authors:  Nicholas D Bland; Cuihua Wang; Craig Tallman; Alden E Gustafson; Zhouxi Wang; Trent D Ashton; Stefan O Ochiana; Gregory McAllister; Kristina Cotter; Anna P Fang; Lara Gechijian; Norman Garceau; Rajiv Gangurde; Ron Ortenberg; Mary Jo Ondrechen; Robert K Campbell; Michael P Pollastri
Journal:  J Med Chem       Date:  2011-11-08       Impact factor: 7.446

3.  Structural basis for the activity of drugs that inhibit phosphodiesterases.

Authors:  Graeme L Card; Bruce P England; Yoshihisa Suzuki; Daniel Fong; Ben Powell; Byunghun Lee; Catherine Luu; Maryam Tabrizizad; Sam Gillette; Prabha N Ibrahim; Dean R Artis; Gideon Bollag; Michael V Milburn; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang
Journal:  Structure       Date:  2004-12       Impact factor: 5.006

4.  SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.

Authors:  Allen J Duplantier; Elizabeth L Bachert; John B Cheng; Victoria L Cohan; Teresa H Jenkinson; Kenneth G Kraus; Michael W McKechney; Joann D Pillar; John W Watson
Journal:  J Med Chem       Date:  2007-01-25       Impact factor: 7.446

5.  Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 2. Tadalafil analogs.

Authors:  Stefan O Ochiana; Alden Gustafson; Nicholas D Bland; Cuihua Wang; Michael J Russo; Robert K Campbell; Michael P Pollastri
Journal:  Bioorg Med Chem Lett       Date:  2012-02-09       Impact factor: 2.823

6.  Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. Part 1. Sildenafil analogs.

Authors:  Cuihua Wang; Trent D Ashton; Alden Gustafson; Nicholas D Bland; Stefan O Ochiana; Robert K Campbell; Michael P Pollastri
Journal:  Bioorg Med Chem Lett       Date:  2012-02-09       Impact factor: 2.823

7.  The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro.

Authors:  B Räz; M Iten; Y Grether-Bühler; R Kaminsky; R Brun
Journal:  Acta Trop       Date:  1997-11       Impact factor: 3.112

8.  1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

Authors:  S B Christensen; A Guider; C J Forster; J G Gleason; P E Bender; J M Karpinski; W E DeWolf; M S Barnette; D C Underwood; D E Griswold; L B Cieslinski; M Burman; S Bochnowicz; R R Osborn; C D Manning; M Grous; L M Hillegas; J O Bartus; M D Ryan; D S Eggleston; R C Haltiwanger; T J Torphy
Journal:  J Med Chem       Date:  1998-03-12       Impact factor: 7.446

9.  Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.

Authors:  Kristina M Orrling; Chimed Jansen; Xuan Lan Vu; Vreni Balmer; Patrick Bregy; Anitha Shanmugham; Paul England; David Bailey; Paul Cos; Louis Maes; Emily Adams; Erika van den Bogaart; Eric Chatelain; Jean-Robert Ioset; Andrea van de Stolpe; Stèphanie Zorg; Johan Veerman; Thomas Seebeck; Geert Jan Sterk; Iwan J P de Esch; Rob Leurs
Journal:  J Med Chem       Date:  2012-10-08       Impact factor: 7.446

10.  Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure.

Authors:  Chimed Jansen; Huanchen Wang; Albert J Kooistra; Chris de Graaf; Kristina M Orrling; Hermann Tenor; Thomas Seebeck; David Bailey; Iwan J P de Esch; Hengming Ke; Rob Leurs
Journal:  J Med Chem       Date:  2013-03-01       Impact factor: 7.446

View more
  6 in total

1.  Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).

Authors:  Emanuele Amata; Nicholas D Bland; Robert K Campbell; Michael P Pollastri
Journal:  Tetrahedron Lett       Date:  2015-05-20       Impact factor: 2.415

2.  Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.

Authors:  Jennifer L Woodring; Kelly A Bachovchin; Kimberly G Brady; Mitchell F Gallerstein; Jessey Erath; Scott Tanghe; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2017-10-06       Impact factor: 6.514

3.  Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.

Authors:  Stefan O Ochiana; Nicholas D Bland; Luca Settimo; Robert K Campbell; Michael P Pollastri
Journal:  Chem Biol Drug Des       Date:  2014-11-18       Impact factor: 2.817

Review 4.  Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect.

Authors:  Zefeng Zhao; Xufen Dai; Chenyang Li; Xiao Wang; Jiale Tian; Ying Feng; Jing Xie; Cong Ma; Zhuang Nie; Peinan Fan; Mingcheng Qian; Xirui He; Shaoping Wu; Yongmin Zhang; Xiaohui Zheng
Journal:  Eur J Med Chem       Date:  2019-11-16       Impact factor: 6.514

Review 5.  The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!

Authors:  Daniel N A Tagoe; Titilola D Kalejaiye; Harry P de Koning
Journal:  Front Pharmacol       Date:  2015-09-07       Impact factor: 5.810

6.  Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.

Authors:  Irene Sola; Albert Artigas; Martin C Taylor; F Javier Pérez-Areales; Elisabet Viayna; M Victòria Clos; Belén Pérez; Colin W Wright; John M Kelly; Diego Muñoz-Torrero
Journal:  Bioorg Med Chem       Date:  2016-08-22       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.